Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia

Leuk Lymphoma. 2016;57(6):1494-7. doi: 10.3109/10428194.2015.1102243. Epub 2015 Nov 16.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine / analogs & derivatives
  • Antineoplastic Agents / pharmacology*
  • Axl Receptor Tyrosine Kinase
  • Caspases / metabolism*
  • Dose-Response Relationship, Drug
  • Drug Evaluation, Preclinical
  • Drug Therapy, Combination
  • Humans
  • Hydrazones / pharmacology*
  • Inhibitory Concentration 50
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
  • Leukemia, Lymphocytic, Chronic, B-Cell / metabolism*
  • Piperazines / pharmacology*
  • Piperidines
  • Proto-Oncogene Proteins / antagonists & inhibitors*
  • Pyrazoles / pharmacology*
  • Pyrimidines / pharmacology*
  • Receptor Protein-Tyrosine Kinases / antagonists & inhibitors*
  • Sulfonamides / pharmacology*
  • Tumor Cells, Cultured

Substances

  • 2-(4-(4-(benzyloxy)benzyl)piperazin-1-yl)-N'-(3,5-di-tert-butyl-2-hydroxybenzylidene)acetohydrazide
  • Antineoplastic Agents
  • Hydrazones
  • Piperazines
  • Piperidines
  • Proto-Oncogene Proteins
  • Pyrazoles
  • Pyrimidines
  • Sulfonamides
  • dubermatinib
  • ibrutinib
  • Receptor Protein-Tyrosine Kinases
  • Caspases
  • Adenine
  • Axl Receptor Tyrosine Kinase
  • AXL protein, human